Joaquin Duato, vice chairman of J&J’s executive committee, discusses how the company’s partnering and innovation-building model has evolved — and why.
Outsourced Pharma Chief Editor Louis Garguilo continues his coverage of the current state of China pharma manufacturing by interviewing Diana Francis, VP of quality and compliance for BeiGene.
“A partnering deal with a bigger pharma company would certainly help us through [the Phase 3] process,” explains Jeff Davidson, CEO of Keystone Nano, a company that develops nanoparticles that target solid tumors by going after cancer cells and leaving the normal cells intact.
“Making sure we had the money for staff and activities to build the business for the long-term was a key initial step,” explains Dr. Helen Torley, CEO of Halozyme Therapeutics.
An in-depth look at three developers that exemplify the range of new approaches and alternatives in the IO combo space: Oncosec Medical, Heat Biologics, and Rexahn.
Industry experts answer questions around future biopharma manufacturing trends, challenges, technologies, performance metrics, risk mitigation, people, and outsourcing.
We connected with a collection of biopharma financial experts to get you prepared for JPM, BTS, and the BIO CEO & Investors Conference in the first quarter of 2019.
Biopharma executives in companies of all sizes share their views on whether the now dominant life sciences industry business model, with its focus on rare diseases affecting small patient populations, allows companies to meet their historical public-health obligation.
What does the future hold for oncology trials, which now comprise around 80 percent of all clinical research? We spoke to three experts who shared their insights into where the industry is headed in 2019 and beyond.
We asked multiple biopharma CEOs everything from which executives or companies they pay close attention to in and outside of their industry, to questions about geopolitical issues, tech trends, and everything in between.
To get to a full digital dialogue that includes everything from AI to blockchain to machine learning, drug sponsors and CDMOs alike will need to muster their resources to usher in what the rest of the world already calls Industry 4.0.
Though the FDA has outlined many promising efforts to help the U.S. biosimilar market grow, the biosimilar industry’s public comments reveal an increasing need for the U.S. government healthcare agencies to take even greater charge of biosimilar policy in 2019.
The ARM Foundation for Cell and Gene was launched in June, and it marks a new stage in development of the RM space as it moves from an early era or “promise” to one of fulfillment. Today, nearly 900 companies worldwide are developing RM therapies.
Liz Barrett recently sat down with Life Science Leader to share some of the formative experiences that shaped her into the leader she has become, including one of the most recent challenges she is embracing at Novartis.
Intellia Therapeutics CEO, John Leonard, M.D., provides insight into why he entered industry, and his drive to be an entrepreneur.
Dr. Helen Torley, president and CEO of Halozyme Therapeutics, shares a story of how the biopharmaceutical industry makes a difference.
Halozyme Therapeutics’ president and CEO, Dr. Helen Torley, discusses her path to the c-suite, including the formative experience that best prepared her for becoming a CEO.
The Netherlands’ biopharma press tour concludes in Amsterdam with presentations (e.g., AIMM Therapeutics) and guided tours of the O2 building and the National Screening Laboratory (NSS) for Sanquin.
Day 3 of the Netherlands’ biopharma press tour begins with presentations at the Utrecht Science Park (USP).
